- Raised $43.7M funding round, Mar 2020
- Raised $10M funding round, Oct 2015
- Raised $6M grant led by Office of the Chief Scientist, Mar 2009
About
Protalix BioTherapeutics is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant-cell-based protein expression system. The company's pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets. Protalix gained FDA approval for a plant-cell culture-expressed protein. Elelyso (taliglucerase alfa for injection) is the company's first drug product produced by ProCellEx. Elelyso was approved for marketing by the FDA in May 2012, soon followed by approval from multiple regulatory agencies including the EMA, Australian TGA, Brazilian ANVISA, and the Israeli Ministry of Health. The product has been licensed to Pfizer. The Protalix ProCellEx platform has the ability to manufacture complex proteins, antibodies, and vaccines and to orally deliver certain therapeutic proteins as demonstrated in animal models.
Funding history · 6 rounds · $159.9M total
Q&A
- What is Protalix BioTherapeutics' primary focus?
- Protalix BioTherapeutics is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant-cell-based protein expression system.
- When was Protalix BioTherapeutics founded?
- Protalix BioTherapeutics was founded in January 1994.
- What is the status of Protalix BioTherapeutics?
- Protalix BioTherapeutics is an active public company, listed on AMEX since December 2006, TASE since November 2010, and NYSE since March 2011.
- What was Protalix BioTherapeutics' most recent funding round?
- In March 2020, Protalix BioTherapeutics raised $43,700,000 from investors including.
- What is Protalix BioTherapeutics' total funding raised to date?
- Protalix BioTherapeutics has raised a total of $159,900,000 in funding.
- Which of Protalix BioTherapeutics' products has received FDA approval?
- Protalix BioTherapeutics gained FDA approval for Elelyso (taliglucerase alfa for injection) in May 2012. This product is produced by their ProCellEx platform and has been licensed to Pfizer.
- How many employees does Protalix BioTherapeutics have?
- Protalix BioTherapeutics has 51-200 employees.
- What is the market capitalization of Protalix BioTherapeutics?
- Protalix BioTherapeutics has a market capitalization of $79,181,384.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | protalix.com |
|---|---|
| linkedin.com/company/739969 | |
| X / Twitter | twitter.com/protalix_bio |
| facebook.com/ProtalixBio | |
| Wikipedia | en.wikipedia.org/wiki/Protalix_BioTherapeutics |
| Wikidata | wikidata.org/wiki/Q7251166 |
Identifiers & details
| Founded | 1994-1 |
|---|---|
| Employees (exact) | 194 |
| Market cap | $79.2M |
| Status reason | Public on AMEX on Dec, 2006;Public on TASE on Nov, 2010;Public on NYSE on Mar, 2011; |
| Wikidata QID | Q7251166 |
Radar intelligence
Web history (Wayback)
| Domain | protalix.com |
|---|
Wikidata
| QID | Q7251166 |
|---|
Certificate / subdomain footprint
| Subdomains | 8 |
|---|